TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00379405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir/Ritonavir : 2 capsules (500 mg) / 12 hours
Description: Saquinavir/Ritonavir: 2 capsules (500 mg) / 12 hours
Study: NCT04734613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Description: Yang style Tai Chi 16 movements

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self management
Description: health education and dietary counseling
Study: NCT03272204

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No pubic hair
Description: Natural pubic hair to fully removed pubic hair

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pubic Hair
Description: Removed pubic hair to natural pubic hair
Study: NCT02059109

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hands on Assembly of Belmont Rapid Infuser
Description: Participants will work individually or in pairs to assemble the Belmont Rapid Infuser in addition to completing the traditional training methods.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hands on Assembly of Belmont Rapid Infuser
Description: Participants will work individually or in pairs to assemble the Belmont Rapid Infuser in addition to completing the traditional training methods.
Study: NCT00863122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1500 mg lapatinib by mouth per day for 10 days
Study: NCT02442908

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrifriend Cachexia
Description: 2 daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric placebo
Description: 2 daily for 12 weeks
Study: NCT01899092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-034
Description: The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given.
Study: NCT01579227

Intervention type: DEVICE
Intervention: Topical Tocotrienol (TCT)
Description: Natural Form Vitamin E topical cream(TCT)

Intervention type: DIETARY_SUPPLEMENT
Intervention: Oral Tocotrienol Capsules (TCT)
Description: Natural Form Vitamin E Oral capsules (TCT)
Study: NCT02441231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visbiome
Description: Visbiome probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01579227

Intervention type: DIETARY_SUPPLEMENT
Intervention: Oral Tocotrienol Capsules (TCT)
Description: Natural Form Vitamin E Oral capsules (TCT)

Intervention type: DEVICE
Intervention: Tamoxifen Cream
Description: Tamoxifen cream

Intervention type: DEVICE
Intervention: Tamoxifen Cream
Description: Tamoxifen cream

Intervention type: DEVICE
Intervention: Placebo cream
Description: Placebo cream

Intervention type: DEVICE
Intervention: Placebo cream
Description: Placebo cream

Intervention type: DEVICE
Intervention: Placebo cream
Description: Placebo cream

Intervention type: DIETARY_SUPPLEMENT
Intervention: placebo capsule
Description: placebo capsule

Intervention type: DIETARY_SUPPLEMENT
Intervention: placebo capsule
Description: placebo capsule
Study: NCT03962179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VACStent
Description: Evaluation of the suitability of the medical device for sealing leaks in the gastrointestinal tract
Study: NCT00890825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD6244
Description: oral capsules, 75mg twice daily
Study: NCT01167764

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tranexamic acid, placebo
Description: tranexamic acid 250mg tid for 1 months vs. placebo for 1 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid, placebo
Description: tranexamic acid 250mg tid for 1 months vs. placebo for 1 months
Study: NCT00890825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75mg/m2 iv on day 1 of every 21 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: docetaxel
Description: 75mg/m2 iv on day 1 of every 21 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT01508169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot orthosis (Orthotics Unit of the Clinical Hospital of UNICAMP)
Description: Custom foot orthoses made of ethylene-vinyl acetate (EVA) with medial arch supports and metatarsal pads (supporting the diaphysis of the second to fourth metatarsals) that were manufactured by the Orthotics and Prostheses Unit of the Clinical Hospital of UNICAMP.
Study: NCT03659799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin FiAsp
Description: An insulin bolus of FiAsp will be given 5 minutes before breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin FiAsp
Description: An insulin bolus of FiAsp will be given 5 minutes before breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: An insulin bolus of Aspart will be given 5 minutes before breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: An insulin bolus of Aspart will be given 5 minutes before breakfast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 60-minutes postprandial exercise
Description: A 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 60-minutes postprandial exercise
Description: A 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 120-minutes postprandial exercise
Description: A 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 120-minutes postprandial exercise
Description: A 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast
Study: NCT04035252

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid artery reactivity test (CAR-test)
Description: The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved. During this test as well the carotid artery as the abdominal aorta will be visualized using ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid artery reactivity test (CAR-test)
Description: The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved. During this test as well the carotid artery as the abdominal aorta will be visualized using ultrasound.

Intervention type: DIAGNOSTIC_TEST
Intervention: Carotid artery reactivity test (CAR-test)
Description: The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved. During this test as well the carotid artery as the abdominal aorta will be visualized using ultrasound.
Study: NCT00806910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conivaptan
Description: IV Vaprisol initially at 20 mg IV injection over 30 minutes, followed by a 20 mg IV infusion over the next 24 hours (i.e. 20 mg bolus, 20 mg continuous infusion approximately 24 hrs).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (will be given at the same rate of Vaprisol given in the treatment arm)
Study: NCT03200834

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right Hemicolectomy with D2 lymph node dissection
Description: Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right Hemicolectomy with D3 lymph node dissection
Description: Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).
Study: NCT03195816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive training
Description: Experimental group will receive 1 year of a computer-based cognitive stimulation program, first 6 months, 60-minutes twice a week and next 6 months once a week training in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
Study: NCT00988884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm at Day 1, Month 2, and Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V503
Description: V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm at Day 1, Month 2, and Month 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Menactra™ (Concomitant)
Description: Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Adacel™ (Concomitant)
Description: Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Menactra™ (Non-Concomitant)
Description: Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Adacel™ (Non-concomitant)
Description: Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
Study: NCT03865082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilsotolimod
Description: 9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Week 0 Day 1 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days.
Study: NCT03062020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QUIPP
Description: Information required by QUIPP tool will be introduced ( obstetrical history, cervical length and quantitative fetal fibronectin value) and a percentage of risk of preterm birth will be given. Women with a high-risk value will be managed in Preterm Birth Prevention Clinic and women with low-risk value will be followed-up in a low-risk unit.
Study: NCT00750724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg sodium hyaluronate GO ON
Description: 25 mg sodium hyaluronate, 2 ml., intraarticular weekly for 5 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline,2 ml., intraarticular weekly for 5 weeks
Study: NCT02179411

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tilt test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tilt test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tilt test
Study: NCT03028753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bladder scan post void residual
Description: After voiding on the commode, all subjects will have a post void residual measured by bladder scanner

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Straight catheter post void residual
Description: After voiding on the commode and having a post void residual measured by bladder scanner, all subjects will have a post void residual measured by straight catheter performed with usual sterile technique.
Study: NCT02996630

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sonography
Description: Fetal Ultrasound exploration
Study: NCT03028753

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Back fill voiding trial
Description: Prior to catheter removal, all subjects will undergo a back fill voiding trial. The bag of the foley catheter will be removed and the subjects bladder will be filled with 300cc of normal saline (or as much as they can tolerate). The foley catheter will then be removed and the subject will be asked to void on the commode. The voided volume will be measured.
Study: NCT00298259

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operative fixation of fractured ribs
Description: ORIFof fractured ribs in flail chest patients
Study: NCT03412747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-defined timepoints in dose regimen 1 and/or dose regimen 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-defined timepoints in dose regimen 1 and/or dose regimen 2.
Study: NCT02996630

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sonography
Description: Fetal Ultrasound exploration

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Fetal MRI for brain study

Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Fetal MRI for brain study

Intervention type: OTHER
Group type: OTHER
Intervention: Bailey Test
Description: Neurodevelopment paediatric assessment test performed at 2 years of age.
Study: NCT03412747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-defined timepoints in dose regimen 1 and/or dose regimen 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab will be administered according to the labeling recommendations.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products (IMP).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products (IMP).
Study: NCT02996630

Intervention type: OTHER
Group type: OTHER
Intervention: Bailey Test
Description: Neurodevelopment paediatric assessment test performed at 2 years of age.
Study: NCT03412747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products (IMP).
Study: NCT05343520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercises
Description: Pelvic floor muscle exercises were applied to the pregnant women in the experimental group from the 30th gestational week to the 6th postpartum week.
Study: NCT00776217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg orally disintegrating tablets
Study: NCT02996630

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical intervention
Description: Congenital Heart Disease repair

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brain monitoring
Description: EEG and continuous brain oximetry before surgery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cord blood sample
Description: Cord blood samples will be taken after birth in both groups.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cord blood sample
Description: Cord blood samples will be taken after birth in both groups.
Study: NCT03225235

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients With Low and Intermediate Risk of Progression Prostate Cancer
Study: NCT06522789

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corneal cross-linking procedure
Description: Standard Dresden protocol corneal cross-linking procedure The CXL procedure adhered to the standard Dresden protocol. All patients received topical anaesthetic (Tetracaine HCL 0.5%, Alcon Forth Worth, Texas) and a miotic (Isopto Carpine 2% HCl, Alcon, Fort Worth, Texas) drops 30 minutes before the procedure. The periocular region and conjunctival sac were washed with 10% povidone-iodine (Betadine 10%, Alcaloid, Skopje). Manual epithelial scraping with a crescent knife followed. Pachymetry was kept over 400 μm during the procedure and measured with an ultrasound hand pachymeter (Pocket II, Quantel Medical, Cournon d'Auvergne, France). Riboflavin (Peschke D, Peschke Trade, Huenenberg, Switzerland) was applied every 3 minutes for 30 minutes. We performed corneal UV-A radiation with a wavelength of 370 nm and energy of 3mW using a UVA CXL lamp (VEGA CBM-X-Linker, Carleton Optical, Chesham, UK) for 30 minutes (6 cycles of 5 minutes each).
Study: NCT02498288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin: Reference Medication 1
Description: Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin: Reference Medication 2
Description: Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin: Test Medication
Description: Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.
Study: NCT01735448

Intervention type: OTHER
Intervention: Focus group
Description: Initially, ten focus groups with an average sample size of 5-7 participants each will be performed in two communities within South Australia, one being Adelaide and the other Murray Bridge, this includes focus groups held with healthcare workers.~The proposed focus groups will be conducted by experienced mediators who have undertaken Aboriginal cultural awareness training and have experience in qualitative research methods. Both mediators have also been involved in all aspects of project development and consultation with Aboriginal Elders and key stakeholders since its conception.~We will be using topic guides (reviewed by Aboriginal Elders and researchers) that will be semi-structured with open-ended questions designed to encourage group discussion around smoking cessation and the use of pharmacotherapies in particular, in addition to other objectives identified during the consultation phase of this research.

Intervention type: OTHER
Intervention: Focus group
Description: Initially, ten focus groups with an average sample size of 5-7 participants each will be performed in two communities within South Australia, one being Adelaide and the other Murray Bridge, this includes focus groups held with healthcare workers.~The proposed focus groups will be conducted by experienced mediators who have undertaken Aboriginal cultural awareness training and have experience in qualitative research methods. Both mediators have also been involved in all aspects of project development and consultation with Aboriginal Elders and key stakeholders since its conception.~We will be using topic guides (reviewed by Aboriginal Elders and researchers) that will be semi-structured with open-ended questions designed to encourage group discussion around smoking cessation and the use of pharmacotherapies in particular, in addition to other objectives identified during the consultation phase of this research.
Study: NCT00776217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: loratadine 10 mg orally disintegrating tablets
Study: NCT00558038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: AST-120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactulose
Description: lactulose
Study: NCT02720302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOFT
Description: SOFT is based on systemic and solution-focused theories to change lifestyle and has shown positive effects on children with respect to the degree of obesity, physical fitness, self-esteem and family functioning.
Study: NCT02720302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeleSOFT
Description: The therapists communicate with the overweight child and his/her family by the SOFT method on distance by use of video.
Study: NCT01405833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00010 (Neublastin)
Description: Multiple doses, weight-based IV administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose IV matched placebo
Study: NCT04473898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Aerobic exercises using all body muscles and that one can do on their own after being shown online

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training
Description: Aerobic exercises using all body muscles and that one can do on their own after being shown online

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patient education about covid-19 and hygiene education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patient education about covid-19 and hygiene education

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Patient Education
Description: Patient education about covid-19 and hygiene education
Study: NCT04473898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Exercise Training
Description: Respiratory exercises that one can do on their own after being shown online